共 97 条
[1]
Baigent C(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-1681
[2]
Blackwell L(2004)Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci U S A 101 7100-7105
[3]
Emberson J(2005)Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat Genet 37 161-165
[4]
Holland LE(2008)Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 J Lipid Res 49 394-398
[5]
Reith C(2008)Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment Clin Chem 54 1038-1045
[6]
Bhala N(2007)Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression Biochem Biophys Res Commun 357 707-711
[7]
Maxwell KN(2010)Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels J Lipid Res 51 345-351
[8]
Breslow JL(2009)A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Proc Natl Acad Sci U S A 106 9820-9825
[9]
Cohen J(2015)ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2996-3003
[10]
Pertsemlidis A(2015)PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 331-340